Randomized, Controlled, Open Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of PLB1004 Versus Platinum-based Chemotherapy With or Without Sintilimab of Advanced NSCLC With EGFR Exon 20 Ins Mutations
Latest Information Update: 04 Mar 2024
Price :
$35 *
At a glance
- Drugs Andatinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed; Sintilimab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Avistone Pharmaceuticals
- 04 Mar 2024 New trial record